Denali Therapeutics (NASDAQ:DNLI) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Denali Therapeutics (NASDAQ:DNLI) in a research note published on Thursday morning, Benzinga reports. The firm currently has a $105.00 target price on the stock.

A number of other research analysts also recently issued reports on DNLI. Stifel Nicolaus cut their price objective on Denali Therapeutics to $30.00 in a research note on Tuesday, May 9th. Wedbush dropped their price target on shares of Denali Therapeutics from $37.00 to $31.00 and set an outperform rating for the company in a research report on Wednesday, August 9th. TheStreet upgraded shares of Denali Therapeutics from a d rating to a c- rating in a research report on Friday, August 11th. Finally, Cantor Fitzgerald reaffirmed an overweight rating and issued a $85.00 target price on shares of Denali Therapeutics in a report on Tuesday, August 22nd. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat, Denali Therapeutics currently has an average rating of Buy and a consensus price target of $55.64.

Denali Therapeutics Trading Down 1.0 %

Shares of NASDAQ DNLI opened at $23.09 on Thursday. Denali Therapeutics has a 12-month low of $21.74 and a 12-month high of $34.78. The firm has a market capitalization of $3.17 billion, a price-to-earnings ratio of -21.18 and a beta of 1.31. The firm has a 50 day moving average of $26.92 and a 200 day moving average of $27.08.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Tuesday, August 8th. The company reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $1.99. The company had revenue of $294.10 million for the quarter, compared to analysts’ expectations of $39.51 million. Denali Therapeutics had a negative return on equity of 12.81% and a negative net margin of 37.42%. Denali Therapeutics’s revenue for the quarter was up 460.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.48) EPS. Sell-side analysts predict that Denali Therapeutics will post -1.24 EPS for the current year.

Insider Activity

In related news, CEO Ryan J. Watts sold 2,526 shares of the business’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $25.03, for a total value of $63,225.78. Following the sale, the chief executive officer now directly owns 2,239,913 shares in the company, valued at $56,065,022.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, insider Alexander O. Schuth sold 10,000 shares of the stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $29.60, for a total transaction of $296,000.00. Following the completion of the transaction, the insider now directly owns 528,691 shares in the company, valued at approximately $15,649,253.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Ryan J. Watts sold 2,526 shares of the business’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $25.03, for a total transaction of $63,225.78. Following the completion of the sale, the chief executive officer now owns 2,239,913 shares in the company, valued at approximately $56,065,022.39. The disclosure for this sale can be found here. Insiders sold a total of 38,083 shares of company stock worth $972,610 over the last 90 days. Corporate insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On Denali Therapeutics

Several institutional investors have recently bought and sold shares of the business. Baillie Gifford & Co. raised its position in shares of Denali Therapeutics by 1.5% during the 1st quarter. Baillie Gifford & Co. now owns 15,352,111 shares of the company’s stock valued at $353,713,000 after buying an additional 232,637 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Denali Therapeutics by 6.7% in the 2nd quarter. BlackRock Inc. now owns 10,106,275 shares of the company’s stock worth $298,236,000 after purchasing an additional 631,878 shares during the period. Vanguard Group Inc. increased its position in shares of Denali Therapeutics by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 8,402,031 shares of the company’s stock valued at $257,858,000 after purchasing an additional 99,530 shares during the last quarter. Temasek Holdings Private Ltd raised its holdings in Denali Therapeutics by 5.8% during the 1st quarter. Temasek Holdings Private Ltd now owns 6,895,992 shares of the company’s stock valued at $158,884,000 after buying an additional 379,951 shares during the period. Finally, Wellington Management Group LLP lifted its position in Denali Therapeutics by 1.5% in the first quarter. Wellington Management Group LLP now owns 5,200,460 shares of the company’s stock worth $119,819,000 after buying an additional 78,730 shares during the last quarter. Institutional investors own 78.04% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative and lysosomal diseases in the United States and internationally. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease; TAK-594/DNL593, which is in Phase I/II clinical trials for the treatment of frontotemporal dementia-granulin; TAK-920/DNL919, which is in Phase I clinical trials for the treatment of Alzheimer's disease.